Alex Bataller Torralba, MD, PhD
Department of Leukemia, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2022 | University of Barcelona, Barcelona, ES, PhD in Translational Medicine |
| 2014 | University of Barcelona, Barcelona, ES, MD |
Postgraduate Training
| 2022-null | Leukemia Fellowship, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2021-null | Master's Degree, Bioinformatics and Biostatistics, Universitat Oberta de Catalunya, Barcelona |
| 2020-2021 | Expert in Acute Myeloid Leukemia, CEU San Pablo University |
| 2019-2020 | Master's Degree, Molecular Oncology, Rey Juan Carlos University, Madrid |
| 2018-2019 | Masters' Degree, Hematopoietic stem cell transplantation, University of Valencia, Valencia |
| 2015-2019 | Medico Interno Residente (MIR), National Medical Board, Barcelona |
| null-2019 | ECFMG Certification of the United States Medical Licensing Examination (USMLE), Educational Commission for Foreign Medical Graduates |
| null-2019 | European Hematology Exam, European Hematology Association (EHA), Amsterdam |
Board Certifications
| null | Hematology and Hemotherapy, Ministry of Health, Spain, 2019 |
Experience & Service
Academic Appointments
Pre-doctoral Researcher, August Pi i Sunyer Biomedical Research institute (IDIBAPS) and Josep Carreras Leukemia Research Institute, Barcelona, 2019 - 2022
Administrative Appointments/Responsibilities
Chief fellow, Department of Leukemia Fellowship, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2023 - 2024
Chief resident, Department of Hematology Residency Program, Hospital Clinic de Barcelona, Barcelona, 2018 - 2019
Elected member of the Education Commission, Hospital Clinic de Barcelona, Barcelona, 2017 - 2019
Other Appointments/Responsibilities
Hematology and Immunology lecturer, Academia de estudios AMIR, Madrid, 2016 - 2022
Student Mentor, Academia de estudios AMIR, Madrid, 2014 - 2015
Honors & Awards
| 2024 | Clinical Resident/Fellow Excellence Award for Teamwork, MD Anderson Cancer Center |
| 2020 | Abstract Achievement Award, American Society of Hematology, Virtual meeting |
| 2020 | MSD Grant for the most outstanding resident of the promotion, Hospital Clinic de Barcelona, Barcelona, Spain |
| 2020 | Travel grant, European Hematology Association (EHA), Amsterdam, Netherlands |
| 2019 | Investigation grant, Spanish Foundation of Hematology and Hemotherapy, Valencia, Spain |
| 2019 | Excellence scholarship, Spanish Association against Cancer (AECC), Madrid, Spain |
| 2018 | Abstract Achievement Award, American Society of Hematology, San Diego, California |
| 2018 | Best abstract award,, Catalan Society of Hematology and Hemotherapy, Barcelona, Spain |
| 2018 | Emili Letang Residency Award, Hospital Clínic de Barcelona, Barcelona, Spain |
| 2018 | Bolsa de Viaje, Spanish Society of Hematology and Hemotherapy, Madrid, Spain |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Bazinet, A, Bataller Torralba, A, Kadia, TM, Daver, N, Short, NJ, Yilmaz, M, Sasaki, K, DiNardo, C, Borthakur, G, Issa, GC, Bouligny, IM, Pierce, S, Garcia-Manero, G, Ravandi-Kashani, F, Kantarjian, HM. A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia. Cancer 131(6), 2025. e-Pub 2025. PMID: 40097915.
- Gener-Ricos G, Bataller A, Rodriguez-Sevilla JJ, Chien KS, Quesada AE, Almanza-Huante E, Hammond D, Sasaki K, DiNardo C, Kadia T, Daver N, Borthakur G, Issa GC, Short NJ, Kanagal-Shamanna R, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. NPM1-mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentage. Cancer 130(20):3452-3462, 2024. e-Pub 2024. PMID: 38896064.
- Bataller A, Gener-Ricos G, Almanza-Huante E, Chien KS, Urrutia S, Bazinet A, Rodriguez-Sevilla JJ, Hammond D, Sasaki K, Takahashi K, DiNardo CD, Ravandi F, Borthakur G, Kadia TM, Kanagal-Shamanna R, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm. Blood Adv 8(11):2695-2706, 2024. e-Pub 2024. PMID: 38513082.
- Bataller A, Kantarjian H, Bazinet A, Kadia T, Daver N, DiNardo CD, Borthakur G, Loghavi S, Patel K, Tang G, Sasaki K, Short NJ, Yilmaz M, Issa GC, Alvarado Y, Montalban-Bravo G, Maiti A, Abbas HA, Takahashi K, Pierce S, Jabbour E, Garcia-Manero G, Ravandi F. Outcomes and genetic dynamics of acute myeloid leukemia at first relapse. Haematologica 109(11):3543-3556, 2024. e-Pub 2024. PMID: 38695144.
- Bataller A, Montalban-Bravo G, Bazinet A, Alvarado Y, Chien K, Venugopal S, Ishizawa J, Hammond D, Swaminathan M, Sasaki K, Issa GC, Short NJ, Masarova L, Daver NG, Kadia TM, Colla S, Qiao W, Huang X, Kanagal-Shamanna R, Hendrickson S, Ravandi F, Jabbour E, Kantarjian H, Garcia-Manero G. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study. Lancet Haematol 11(3):e186-e195, 2024. e-Pub 2024. PMID: 38316133.
- Bataller A, Bazinet A, DiNardo CD, Maiti A, Borthakur G, Daver NG, Short NJ, Jabbour EJ, Issa GC, Pemmaraju N, Yilmaz M, Montalban-Bravo G, Takahashi K, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax. Blood Adv 8(4):927-935, 2024. e-Pub 2024. PMID: 38113472.
- Bataller A, Loghavi S, Gerstein Y, Bazinet A, Sasaki K, Chien KS, Hammond D, Montalban-Bravo G, Borthakur G, Short N, Issa GC, Kadia TM, Daver N, Tang G, Quesada A, Patel KP, Ravandi F, Fiskus W, Mill CP, Kantarjian HM, Bhalla K, Garcia-Manero G, Oran B, DiNardo CD. Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants. Am J Hematol 98(11):1780-1790, 2023. e-Pub 2023. PMID: 37665752.
- Bataller A, Haddad FG, Issa GC, Sasaki K, Jabbour E, Borthakur G, Ferrajoli A, Short NJ. Sudden lymphoid blast crisis after tyrosine kinase inhibitor discontinuation in chronic phase chronic myeloid leukemia: cautionary tales for appropriate molecular monitoring. Leuk Lymphoma 64(3):746-749, 2023. e-Pub 2023. PMID: 36657414.
- Guijarro, F, Bataller Torralba, A, Díaz-Beyá, M, Garrido, A, Coll-Ferrà, C, Vives, S, Salamero, O, Valcárcel, D, Tormo, M, Arnan, M, Sampol, A, Castaño-Díez, S, Martinez, C, Suárez-Lledó, M, Fernández-Avilés, F, Hernández-Boluda, JC, Ribera, JM, Rovira, M, Brunet, S, Sierra, J, Esteve, J. Long-term outcomes in patients with relapsed/refractory acute myeloid leukemia and other high-risk myeloid malignancies after undergoing sequential conditioning regimen based on IDA-FLAG and high-dose melphalan. Bone marrow transplantation 57(8):1304-1312, 2022. e-Pub 2022. PMID: 35643942.
- Bataller Torralba, A, Garrido, A, Guijarro, F, Oñate, G, Díaz-Beyá, M, Arnan, M, Tormo, M, Vives, S, de Llano, MQ, Coll, R, Gallardo, D, Vall-Llovera, F, Escoda, L, Garcia-Guiñon, A, Salamero, O, Sampol, A, Merchan, B, Bargay, J, Castaño-Díez, S, Esteban, D, Oliver-Caldés, A, Rivero, A, Mozas, P, López-Guerra, M, Pratcorona, M, Zamora, L, Costa, D, Rozman, M, Nomdedeu, J, Colomer, D, Brunet, S, Sierra, J, Esteve, J. European LeukemiaNet 2017 risk stratification for acute myeloid leukemia. Blood Advances 6(4):1193-1206, 2022. e-Pub 2022. PMID: 34911079.
- Oñate, G, Bataller Torralba, A, Garrido, A, Hoyos, M, Arnan, M, Vives, S, Coll, R, Tormo, M, Sampol, A, Escoda, L, Salamero, O, Garcia, AM, Bargay, J, Aljarilla, A, Nomdedeu, J, Esteve, J, Sierra, J, Pratcorona, M. Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1. Blood Advances 6(3):882-890, 2022. e-Pub 2022. PMID: 34516636.
Other Articles
- Perez-Amill, L, Bataller Torralba, A, Delgado, J, Esteve, J, Juan, M, Klein-González, N Advancing CART therapy for acute myeloid leukemia. Frontiers in immunology 14, 2023. PMID: 38098489.
- Molina, O, Bataller Torralba, A, Thampi, N, Ribera, J, Granada, I, Velasco, P, Fuster, JL, Menendez, P Near-haploidy and low-hypodiploidy in b-cell acute lymphoblastic leukemia. Cancers 14(1), 2022. PMID: 35008193.
Letters to the Editor
- Bataller A, DiNardo CD, Bazinet A, Daver NG, Maiti A, Borthakur G, Short N, Sasaki K, Jabbour EJ, Issa GC, Pemmaraju N, Yilmaz M, Montalban-Bravo G, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM. Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups. Am J Hematol 99: 792-796, 2024.
- Bataller A, Abuasab T, McCall D, Wang W, Cuglievan B, Issa GC, Jabbour E, Short N, DiNardo CD, Tang G, Garcia-Manero G, Kantarjian HM, Sasaki K. Myeloid lineage switch in KMT2A-rearranged acute lymphoblastic leukemia treated with lymphoid lineagedirected therapies. Haematologica 109: 293-297, 2024.
- Almanza-Huante E, Bataller A, Urrutia S, Gener-Ricos G, Briski RE, Kanagal-Shamanna R, Lu KH, Westin SN, Yap TA, Takahashi K, Ravandi F, Alvarado Y, Kadia T, Sasaki K, Kantarjian HM, Garcia-Manero G. Outcomes of patients with therapy-related myeloid neoplasms after treatment with poly(ADP-ribose) polymerase proteins inhibitors for solid tumours. Br J Haematol 201: e25-e29, 2023.
- Bataller A, Chien KS, Sasaki K, Montalban-Bravo G, Kanagal-Shamanna R, Urrutia S, Almanza-Huante E, Gener-Ricos G, Ravandi F, Jabbour E, Kadia T, Borthakur G, Garcia-Manero G. PHF6 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia. Leuk Res 127: 107044, 2023.
Selected Presentations & Talks
National Presentations
- 2024. Genetic dynamics and outcomes of AML at first relapse Hematology/Oncology Grand Rounds. Invited. Chicago, IL, US.
International Presentations
- 2024. Understanding and facing R/R AML. Invited. II Annual Meeting of the CETLAM group. Barcelona, ES.
- 2023. Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 mutations Update in diagnosis and management of acute myeloid leukemia. Invited. Barcelona, ES.
Formal Peers
- Design and validation of a CD123-directed CAR-T model for relapse/refractory acute myeloid leukemia. Barcelona, ES.
- Immunotherapy in acute myeloid leukemia. Barcelona, ES.
- Anaplastic lymphoma with peripheral blood expression. Barcelona, ES.
- KMT2A-Partial tandem duplications (MLL-PTD) in AML. Barcelona, ES.
- ALK negative Anaplastic lymphoma. Barcelona, ES.
- CLL progression and transformation in the ibrutinib era. Barcelona, ES.
- Early T-cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL). Barcelona, ES.
Grant & Contract Support
| Date: | 2020 - 2022 |
| Title: | Investigation grant FEHH |
| Funding Source: | Spanish Foundation of Hematology and Hemotherapy |
| Role: | Predoctoral researcher |
| Date: | 2019 - 2020 |
| Title: | Emili Letang Residency Award |
| Funding Source: | Hospital Clinic of Barcelona |
| Role: | Predoctoral researcher |
Patient Reviews
CV information above last modified April 16, 2025